Key statistics
As of last trade Axsome Therapeutics Inc (19X:DUS) traded at 151.90, -6.12% below its 52-week high of 161.80, set on Jan 22, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 151.85 |
|---|---|
| High | 152.05 |
| Low | 151.85 |
| Bid | 151.75 |
| Offer | 153.95 |
| Previous close | 153.20 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 50.41m |
| Free float | 42.34m |
| P/E (TTM) | -- |
| Market cap | 9.14bn USD |
| EPS (TTM) | -4.67 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 15:30 GMT.
More ▼
Announcements
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
- Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
- Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
- Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
- Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
More ▼
